2016AScONamesAdvanceoftheYear:CancerImmunotherapy>In 2015, the FDA approved PD-1 /PD-L1 Nivolumab, pembrolizumab )immunotherapies to treat the most commonforms of advanced lung and kidney cancer11
➢In 2015, the FDA approved PD-1 /PD-L1 （ Nivolumab， pembrolizumab ） immunotherapies to treat the most common forms of advanced lung and kidney cancer 2016 ASCO Names Advance of the Year: Cancer Immunotherapy ➢11
概述第一节三、肿瘤免疫治疗的原理肿瘤免疫治疗的原理是通过增强抗肿瘤免疫应答和打破肿瘤的免疫抑制产生抗肿瘤作用。IFN-YIL-10和TGF-BS强化免疫应答打破免疫耐受
肿瘤免疫治疗的原理是通过增强抗肿瘤免疫应答 和打破肿瘤的免疫抑制产生抗肿瘤作用。 三、肿瘤免疫治疗的原理 第一节 概述 强化免疫应答 打破免疫耐受
主要内容第一节概述第二节肿瘤免疫治疗的分类第三节免疫治疗在肿瘤综合治疗中的作用
主要内容 第一节 概述 第二节 肿瘤免疫治疗的分类 第三节 免疫治疗在肿瘤综合治疗中的作用
Types of biological therapiesMAYOCLINICCANCERDRESEARCHUKTypes of biological therapySeveraltypesofbiologicaltherapyexist,including> Monoclonalantibodies(MABs).Adoptivecelltransfer.Angiogenesisinhibitors> CancervaccinesBlood cell growth.Bacillus Calmette-Guerin therapyfactors.Biochemotherapy> Cancer growth blockers.Cancervaccines>Drugsthatblockcancerbloodvessel·Cytokine therapy.Gene therapygrowth (anti angiogenics).Immunoconjugates>InterferonandInterleukin2.Monoclonalantibodies(immunotherapy)·Oncolyticvirustherapy>Genetherapy。Targeteddrug therapy>14
➢ Monoclonal antibodies (MABs) ➢ Cancer vaccinesBlood cell growth factors ➢ Cancer growth blockers ➢ Drugs that block cancer blood vessel growth (anti angiogenics) ➢ Interferon and Interleukin 2 (immunotherapy) ➢ Gene therapy Types of biological therapies ➢14
发挥免疫应答的成员？>免疫细胞>免疫分子/物质
发挥免疫应答的成员？ ➢免疫细胞 ➢免疫分子/物质